Tuberculosis (TB) Diagnostics Market to Grow at a CAGR of 5.6% during 2023-2030; Growing Tuberculosis Incidence in High-Burden Nations to Drive Market Growth

The tuberculosis (TB) diagnostics market size was valued at USD 1.93 billion in 2022. The market is projected to grow from USD 2.17 billion in 2023 to USD 3.19 billion by 2030 at a CAGR of 5.6% during 2023-2030. Fortune Business Insights™ presents this information in its report titled “Tuberculosis (TB) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Type (Culture-based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics, and Others), By End-user (Diagnostics Laboratories and Hospitals), and Regional Forecast, 2023-2030”.

Tuberculosis is a contagious disease caused by a type of bacteria called Mycobacterium tuberculosis. The disease mainly attacks the patient’s lungs and several other body parts such as spine and brain. The growing prevalence of the disease has increased the demand for efficient tuberculosis diagnostics tests to control its spread globally.

Decreased Diagnosis of TB Negatively Affected the Market Growth

The pandemic caused a rapid decrease in TB testing rates across the high-burden nations globally. Key market players experienced a decline in their revenues as sales of TB diagnosis instruments and consumables decreased during the pandemic. In 2021, TB testing increased significantly resulting in a significant rebound for the TB diagnostics market.

F. Hoffmann-La Roche Ltd Acquired GenMark Diagnostics to Expand its Molecular Diagnostics Portfolio

In May 2021, F. Hoffmann-La Roche Ltd fully acquired GenMark Diagnostics for USD 1.8 billion. Through this acquisition, F. Hoffmann-La Roche Ltd expanded its molecular diagnostics portfolio with GenMark Diagnostics’ syndromic testing expertise.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/tuberculosis-tb-diagnostics-market-102009

Growing Tuberculosis Incidence in High-Burden Nations to Drive Market Growth

A significant rise in the incidence of tuberculosis across high-burden nations is driving the market growth. There has been an increase in TB patient population over the past few decades. In 2021, according to the WHO Tuberculosis Report 2021, approximately 10.6 million people had tuberculosis, resulting in 4.5% increase from the cases reported in 2020.

Competitive Landscape

Major Key Players’ Focus on TB Diagnostics Portfolio Expansion to Aid Market Growth

bioMérieux SA dominated the tuberculosis diagnostics market share in 2022. Due to continuous product launches and a strong product portfolio for test types such as IGRA tests, bioMérieux SA was able to dominate the market. bioMérieux SA has a strong product portfolio, which includes VIDAS TB-IGRA. Other key competitors, including Thermo Fisher, Cepheid (Danaher), and Qiagen are focusing on research & development activities to develop innovative tuberculosis diagnostics and strengthen their presence in the market.

Notable Industry Development

• April 2021 – BD (Becton Dickinson and Company) announced the inclusion of its BD MAX Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay in the NAAT class of molecular diagnostic technologies. The World Health Organization (WHO) recognized these technologies as precise diagnostics tests.

List of the Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd (Switzerland)


• bioMérieux SA (France)


• QIAGEN (Netherlands)


• BD (U.S.)


• Cepheid (Danaher) (U.S.)


• Thermo Fisher Scientific Inc. (U.S.)


• Abbott Laboratories (U.S.)


• Hologic, Inc. (U.S.)


• Hain Lifescience GmbH (Germany)


• Oxford Immunotec USA, Inc. (U.K.)

Further Report Findings-

• North America is expected to dominate the market share during the forecast period. The region is also expected to lead the market due to the rising prevalence of tuberculosis, boosting the number of diagnoses being conducted in the region.


• Europe captured a significant market share in 2022. The region witnessed high growth due to the initiatives undertaken by the European government agencies and rising demand for tuberculosis diagnostics such as rapid molecular diagnostics. The growth in the region is also driven by the increasing number of diagnostic labs in European nations such as the U.K.  


• Asia Pacific is estimated to experience significant CAGR during the forecast period. Rising demand among individuals for better treatment, a growing number of TB cases, and improved healthcare infrastructure in key Asian nations are driving the market growth in the region over 2023-2030.


• The Middle East & Africa and Latin America are estimated to experience substantial growth over 2023-2030 due to a rising number of companies considering these regions for geographic expansion.

Table of Segmentation: